<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04163068</url>
  </required_header>
  <id_info>
    <org_study_id>2-078-19</org_study_id>
    <nct_id>NCT04163068</nct_id>
  </id_info>
  <brief_title>The Improving Cancer Aftercare Study.</brief_title>
  <acronym>ICAS</acronym>
  <official_title>The Improving Cancer Aftercare Study. Using Patient and Caregiver Experiences to Assess Treatment Burden and Inform Health Service Design for People After Prostate and Colorectal Cancer. A Qualitative Semi-structured Interview Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aberdeen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Grampian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aberdeen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a qualitative interview study that aims to understand treatment burden in individuals
      who have experienced prostate or colorectal cancer treatment within the past five years. We
      intend to use patient and caregiver experiences to co-design interventions to optimise cancer
      aftercare.

      Treatment burden is the workload of healthcare for patients and the consequences of this
      workload on patient function. Treatment burden has been associated with negative outcomes in
      stroke, heart failure, diabetes, and renal failure. Cancer is increasingly becoming a chronic
      condition, and involves a variety of self-management tasks for patients and their caregivers.
      In this study investigators will investigate treatment burden in people after prostate and
      colorectal cancer. Investigators will seek to understand patient and caregiver perceptions
      about cancer aftercare, and ways that services could be redesigned and improved to reduce
      treatment burden, and improve patient outcomes.

      We will undertake a qualitative interview study, recruiting patients from general practices
      and oncology outpatient clinics who have completed potentially curative treatment for
      prostate or colorectal cancer, or who are on active surveillance or hormonal therapies for
      localised or locally advanced prostate cancer. We will purposively sample, to ensure that
      participants with comorbidities, those from lower socioeconomic groups, and rural dwellers
      are adequately represented. We will conduct interviews according to a schedule, informed by
      conceptual models of burden of treatment, Schwarzer's Health Action Process Approach, and
      Normalisation Process Theory.

      Interviews will be filmed and/or audio-recorded and transcribed. Framework and thematic
      analysis will be used to analyse and synthesise the data. Participants will be given the
      chance to comment on outputs and findings (triangulation).

      Investigators plan to use the results of this study, and excerpts from video interviews
      during co-design events, and to create new interventions to optimise aftercare for patients
      with prostate and colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The number of individuals surviving for more than five years following a cancer diagnosis is
      steadily rising. Cancer is often a long-term condition. Individuals living beyond a cancer
      diagnosis are required to participate in a range of self-management activities, including
      (and not limited to) managing symptoms and comorbidities, self-monitoring for recurrence,
      adjusting to life beyond cancer/managing psychological sequelae, taking medications,
      attending follow-up appointments, and addressing unhealthy behaviours.

      Treatment burden is the workload of healthcare for patients, and the effect that this work
      has on patient functioning and well-being. In the 1960s, Thomas Creer recognised that patient
      participation in their own healthcare was important in achieving disease control in
      paediatric asthma. Since then, &quot;self-management&quot; has been extensively researched and
      conceptualised. In the 1980s, Corbin and Strauss characterised three strands of &quot;work&quot; for
      people with chronic conditions: medical management, for example adhering to medication
      regimens and attending appointments; behavioural management, such as adopting healthier
      lifestyle practices; and the emotional management of adapting to a long-term condition.

      Increasing patient participation in self-management has mostly been viewed as a positive
      strategy through which to improve health outcomes, reduce medical paternalism, and delegate
      some tasks away from over-burdened health and social care systems. Treatment burden is a
      relatively recent concept which highlights the potentially deleterious effects of increasing
      patient workload. Treatment burden is becoming increasingly relevant as more people survive
      into old age, often with combinations of comorbidities (including cancer) for which there are
      multiple available therapeutic agents and complex self-management regimens.

      In diabetes, renal failure, heart failure, and stroke, there is increasing evidence that
      increased treatment burden is associated with reduced quality of life, non-adherence to
      therapeutic regimes, and wasted resources. Treatment burden is modified by patient capacity:
      those with lower self-efficacy, low levels of social support, financial difficulties, and
      competing personal workload can experience increased treatment burden. In cancer, certain
      large and distinct demographic groups, particularly rural dwellers and the socially deprived,
      have poorer survival after a cancer diagnosis. The mechanisms of these inequities have not
      been adequately explained.

      It is feasible that treatment burden could modify interactions with health services,
      engagement with survivorship activities, and ultimately, cancer outcomes.

      Treatment burden is a relatively recent concept which is under-explored in in cancer
      survivors.

      The objectives of this study are:

        1. To investigate patient perceptions of treatment burden after prostate and colorectal
           cancer.

        2. To determine sources of treatment burden in prostate and colorectal cancer survivors,
           their interactions, and the perceived consequences of treatment burden.

        3. To utilise key concepts from the interviews to build a video narrative, featuring video
           excerpts from participants to ensure that their voices reach a wider audience, including
           professionals. We will use these narratives to improve cancer services through
           co-design.

      Qualitative interview will be conducted with approximately 40 patients, with or without
      linked caregivers. They will be transcribed verbatim, and analysed using Framework and
      thematic analysis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 4, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment burden</measure>
    <time_frame>12 months</time_frame>
    <description>Patient and caregiver perceptions of treatment burden assessed through semi-structured interviews and analysed by Framework and thematic analysis.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Interview with researcher</arm_group_label>
    <description>All participants will participate in an interview with a researcher</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interview</intervention_name>
    <description>The interview will last approximately 45 minutes, will be audio-recorded, transcribed, and analysed</description>
    <arm_group_label>Interview with researcher</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult survivors of prostate or colorectal cancer and their caregivers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals who have a history of prostate or colorectal cancer within the past five
             years (we are interested in recent experiences and most individuals with colorectal
             cancer are discharged by five years from hospital follow up)

          -  Individuals who have or have had localised or locally advanced disease, treated by any
             method, including and not limited to active surveillance, surgery, radiotherapy, or
             chemotherapy.

          -  Adult age 18 years or over

          -  Caregivers for an individual who meets the above criteria, who are aged 18 years or
             over.

        Exclusion Criteria:

          -  â€¢ Individuals who do not wish to participate

               -  Individuals who do not understand and/or speak English

               -  Individuals with significant cognitive impairment, learning difficulty, or
                  communication difficulty such that understanding the nature of the study, the
                  interview questions, or participating in an interview would not be practical

               -  Presence of distant metastases at the time of recruitment, which are being
                  treated with palliative intent (treatment and follow up for these individuals has
                  different aims and format)

               -  Individuals who are currently undergoing or on waiting lists for chemotherapy,
                  radiotherapy, or surgery (for their colorectal or prostate cancer)

               -  Caregivers who do not have a linked patient participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosalind Adam</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aberdeen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosalind Adam</last_name>
    <phone>01224437906</phone>
    <email>rosalindadam@abdn.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Aberdeen</name>
      <address>
        <city>Aberdeen</city>
        <state>UK</state>
        <zip>AB25 2ZD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Rosalind Adam</last_name>
      <phone>01224437906</phone>
      <email>rosalindadam@abdn.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>survivorship</keyword>
  <keyword>qualitative interviews</keyword>
  <keyword>treatment burden</keyword>
  <keyword>cancer aftercare</keyword>
  <keyword>self management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

